ALX ONCOLOGY HOLDINGS INC
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
ALXO$1.11-13.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| Year Ended | |||
|---|---|---|---|
| December 31, | |||
| 2025 | 2024 | 2023 | |
| Operating activities | |||
| Net loss | $(101,695) | $(134,850) | $(160,805) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Stock-based compensation | 12,579 | 27,093 | 26,273 |
| Depreciation and amortization | 706 | 872 | 836 |
| Non-cash lease costs | 1,719 | 1,785 | 1,272 |
| Net accretion of discounts on investments | (1,242) | (4,657) | (6,487) |
| Accretion of term loan discount and issuance costs | 280 | 265 | 250 |
| Impairment charge | 3,175 | — | |
| Loss on disposal of fixed asset | — | 10 | — |
| Changes in operating assets and liabilities | |||
| Prepaid expenses and other current assets | 658 | (692) | (1,291) |
| Other assets | (686) | 7,375 | 1,366 |
| Accounts payable | 421 | (4,024) | 458 |
| Payable and accrued liabilities due to related party | (149) | (394) | (1,107) |
| Accrued expenses and other current liabilities | 2,002 | (12,624) | 11,224 |
| Other non-current liabilities | (1,910) | (2,071) | (2,353) |
| Net cash used in operating activities | (84,142) | (121,912) | (130,364) |
| Investing activities | |||
| Purchase of investments | (51,593) | (107,406) | (246,629) |
| Maturities of investments | 134,391 | 194,109 | 292,560 |
| Purchase of property and equipment | (212) | (447) | (1,274) |
| Net cash provided by investing activities | 82,586 | 86,256 | 44,657 |
| Financing activities | |||
| Proceeds from equity offerings, net of underwriter discounts ($3,795) and issuance costs ($567) | — | — | 58,887 |
| Proceeds from ATM offering, net of commissions | 1,688 | 29,661 | — |
| Proceeds from exercise of stock options under equity incentive plan | 14 | 1,632 | 269 |
| Proceeds from issuance of common stock under employee stock purchase plan | 24 | 351 | 523 |
| Principal payments on finance leases | (929) | (827) | (388) |
| Principal payments on term loan | (435) | — | — |
| Net cash provided by financing activities | 362 | 30,817 | 59,291 |
| Net decrease in cash, cash equivalents and restricted cash | (1,194) | (4,839) | (26,416) |
| Cash, cash equivalents and restricted cash at beginning of year | 17,633 | 22,472 | 48,888 |
| Cash, cash equivalents and restricted cash at end of period | $16,439 | $17,633 | $22,472 |
| Supplemental disclosure | |||
| Cash paid for interest | $1,259 | $1,387 | $1,177 |
| Supplemental disclosure of non-cash investing and financing activities | |||
| Purchase of property and equipment in accounts payable and accrued expenses | $962 | $1,158 | $1,407 |
| Right-of-use asset (modified) acquired under finance leases | $(182) | $1,309 | $2,600 |
| Reconciliation of cash and cash equivalents and restricted cash: | |||
| Cash and cash equivalents | $16,373 | $17,567 | $22,406 |
| Restricted cash (included in other assets) | 66 | 66 | 66 |
| Total cash, cash equivalents and restricted cash | $16,439 | $17,633 | $22,472 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.